FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
FDA approved Novartis' Tafinlar and Mekinist combo for advanced solid tumors with BRAF V600E mutation, following prior therapy progression and no alternatives. Approved for various cancers, including pediatric use, based on trials showing up to 80% response rates in some tumors.
Reference News
FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
FDA approved Novartis' Tafinlar and Mekinist combo for advanced solid tumors with BRAF V600E mutation, following prior therapy progression and no alternatives. Approved for various cancers, including pediatric use, based on trials showing up to 80% response rates in some tumors.